

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Pickar, *et al.*
SERIAL NUMBER: 10/629,123 EXAMINER: Layla Soroush
FILING DATE: July 28, 2003 ART UNIT: 1617
FOR: NOVEL ANTIPSYCHOTIC COMBINATION THERAPIES AND
COMPOSITIONS USEFUL THEREIN

MAIL STOP AMENDMENT


Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

In response to the Office Action mailed July 27, 2006, Applicants elect Group I, including claims 1-6, 11-30, 31-34, 35-53, 54-62, 63-71 and 75 drawn to a method of treating a serious psychotic mental illness comprising administering a combination of (i) an α 2-adrenergic receptor antagonist and (ii) and atypical antipsychotic neuroleptic, without traverse. In addition in response to the additional species election, Applicants elect (i) α 2-adrenergic receptor antagonists and (ii) atypical antipsychotic neuroleptics to be examined on the merits, without traverse. The Applicants further elect idazoxan as the α 2-adrenergic receptor antagonist and olanzapine as the typical antipsychotic neuroleptic to be examined on the merits, without traverse.

This response is due on or before October 27, 2006. Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 26811-010.

Respectfully submitted,


Ivor R. Elrifi, Reg. No. 39,529
Attorney for Applicants
c/o MINTZ, LEVIN
Tel: (617) 542-6000
Fax: (617) 542-2241
Customer No. 30623

Date: October 26, 2006